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ABSTRACT
Introduction Low back pain (LBP) is recognised globally 
as a prevalent, costly and disabling condition. Recurrences 
are common and contribute to much of the burden of 
LBP. Current evidence favours exercise and education for 
prevention of LBP recurrence, but an optimal intervention 
has not yet been established. Walking is a simple, widely 
accessible, low- cost intervention that has yet to be 
evaluated. This randomised controlled trial (RCT) aims 
to establish the effectiveness and cost- effectiveness of 
a progressive and individualised walking and education 
programme (intervention) for the prevention of LBP 
recurrences in adults compared with no treatment 
(control).
Methods and analysis A pragmatic, two- armed RCT 
comparing walking and education (n=349) with a no 
treatment control group (n=349). Inclusion criteria 
are adults recovered from an episode of non- specific 
LBP within the last 6 months. Those allocated to the 
intervention group will receive six sessions (three face 
to face and three telephone delivered) with a trained 
physiotherapist to facilitate a progressive walking 
programme and education over a 6- month period. The 
primary outcome will be days to first recurrence of an 
episode of activity- limiting LBP. The secondary outcomes 
include days to recurrence of an episode of LBP, days to 
recurrence of an episode of LBP leading to care seeking, 
disability and quality of life measured at 3, 6, 9 and 12 
months and costs associated with LBP recurrence. All 
participants will be followed up monthly for a minimum 
of 12 months. The primary intention- to- treat analysis will 
assess difference in survival curves (days to recurrence) 
using the log- rank statistic. The cost- effectiveness 
analysis will be conducted from the societal perspective.
Ethics and dissemination Approved by Macquarie 
University Human Research Ethics Committee 
(Reference: 5201949218164, May 2019). Findings will 
be disseminated through publication in peer- reviewed 
journals and conference presentations.
Trial registration number ACTRN12619001134112.
INTRODUCTION
Low back pain (LBP) is the leading cause 
of disability worldwide, amounting to 64.9 
million years lived with disability each year.1 
The burden of LBP is in large part a result of 
how common the condition is, with lifetime 
prevalence reported to be as high as 84%.2 
The typical course of LBP is favourable, with 
a systematic review finding marked reduc-
tions in pain and disability within 6 weeks, 
and most patients with LBP recovering within 
12 weeks.3 However, LBP is often recurrent; 
approximately 70% of individuals will expe-
rience at least a minor recurrence within 
12 months following recovery, with more 
than half of these affecting daily activities or 
requiring care seeking.4 These high levels of 
recurrence are a major contributor to the 
large social, personal and economic burden 
of the condition.5–7
Despite strong evidence on the recurrent 
nature of LBP, most previous studies have 
investigated treatment, as opposed to preven-
tion of LBP recurrences. This bias is also 
Strengths and limitations of this study
 ► To our knowledge, this will be the first large, high- 
quality randomised controlled trial investigating the 
effectiveness of a walking and education programme 
for preventing recurrences of low back pain.
 ► Intervention carried out in real- world clinical 
settings.
 ► Analysis of cost- effectiveness in addition to clinical 
effectiveness.
 ► Full participant and therapist blinding is not possible.
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reflected in current clinical practice guidelines which 
principally provide advice on management and rarely 
offer suggestions for prevention. The recently published 
Lancet series on LBP8–10 highlighted this problem and 
identified prevention as a future research priority.
A 2016 systematic review investigating treatments for 
preventing LBP recurrences found only 21 eligible trials. 
The review concluded that there was weak to moderate 
quality evidence that exercise alone or in combination 
with education is effective for preventing LBP recur-
rences when compared with usual care or no treatment 
(35% and 45% risk reductions, respectively).11 These 
findings are further supported by a recently published 
meta- analysis that found exercise alone and exercise 
combined with education can prevent episodes of LBP 
recurrence and LBP- related work absenteeism.12
A concern is that the exercise and education 
programmes shown to be effective for prevention of LBP 
recurrence in past research may not be scalable. The 
barriers to uptake are that the interventions were largely 
either complex, resource intensive or lack flexibility. A 
recent pilot trial explored whether a physiotherapist- led 
exercise and education programme for preventing recur-
rence of LBP was feasible. This trial identified that centre- 
based, long- term programmes, requiring a large time and 
travel commitment, were not acceptable to consumers 
and resulted in low adherence rates.13 Importantly, this 
reduces the likelihood of successful implementation, 
particularly for people who are busy, limited by transpor-
tation, live in rural or remote areas and cannot afford the 
cost of programmes. Identification of an effective, cost- 
efficient and accessible exercise and education model is 
therefore an important development in the LBP field.
Since walking is simple, popular, low cost and can be 
done at a time and place convenient for individuals, it 
warrants investigation as a form of exercise to prevent 
LBP recurrences. Walking programmes have been inves-
tigated for treatment of LBP and appear to be equally as 
effective as other non- pharmacological interventions for 
reducing pain and disability.14–16 However, no previous 
studies have investigated walking in the prevention of 
LBP recurrence.
The WalkBack Trial therefore aims to establish the effec-
tiveness and cost- effectiveness of a progressive and indi-
vidualised walking and education programme compared 
with a no treatment control group, in the prevention of 
LBP recurrences. The trial will focus on prevention of 
recurrences which impact daily activities, but will also 
investigate minor recurrences and recurrences resulting 
in care seeking.
METHODS AND ANALYSIS
The WalkBack Trial is a pragmatic, parallel- group 
randomised controlled trial (RCT) comparing a progres-
sive and individualised walking programme in combina-
tion with education with a no treatment control group, 
in adults recently recovered from an episode of acute 
non- specific LBP (figure 1). The trial will be based 
in Sydney, Australia. Macquarie University Human 
Research Ethics Committee approved the study (refer-
ence number: 5201949218164, 3 May 2019) and the trial 
was prospectively registered with the Australian and New 
Zealand Clinical Trials Registry (ANZCTR). The trial was 
designed according to the Consolidated Standards of 
Reporting Trials statement,17 and is reported according 
to the Standard Protocol Items: Recommendations for 
Interventional Trials statement18 and with reference to 
the Template for Intervention Description and Replica-
tion checklist.19
Patient and public involvement
The rationale and design of this trial was informed 
by patient and public experiences and preferences, 
including the feedback from many participants in our 
previous studies. Prevention of back pain is a priority for 
clinicians and patients.10 20 Our previous feasibility trial 
found that group- based exercises lacked flexibility for 
patients and reduced uptake. This was a primary driver 
in the decision to investigate walking, which is widely 
available, flexible and relatively cheap. In developing this 
project and the application for funding, we included a 
consumer representative on the team, who is an ongoing 
member of the team.
In addition, this trial received input from a broad range 
of stakeholders to obtain National Health and Medical 
Research Council funding and endorsement with 
Australia and New Zealand Musculoskeletal (ANZMUSC) 
Clinical Trials Network. The process included assessment 
of the protocol by both a scientific and consumer advisory 
group that supported the design of the trial and provided 
small suggestions to enhance participant engagement and 
ensure sufficient but non- excessive treatment is provided 
with the hopes to not overload participants. Automated 
email follow- up systems are also used to minimise patient 
burden in completing follow- ups.
When participants have concluded their involvement 
in the trial, they will be sent an email thanking them and 
reminding them that a summary of the results of the data 
can be made available to them on request.
Participants
We will recruit 698 adults who have recovered from a 
recurrence of non- specific LBP within the last 6 months. 
Non- specific LBP is defined as pain in the area between 
the 12th rib and buttock crease not attributed to a specific 
diagnosis such as vertebral fracture or cancer, lasting more 
than 24 hours with a pain intensity >2/10 and causing 
at least somewhat or greater interference with day- to- day 
activities (measured using an adaptation of item PI9 of 
the Patient- Reported Outcomes Measurement Informa-
tion System (PROMIS) item bank to measure pain inter-
ference). Recovery is defined as >7 consecutive days with 
pain no greater than 1 on a 0–10 scale.
People will be ineligible for participation if they meet 
any of the following criteria: any comorbidity preventing 
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participation in a walking programme; are currently 
walking for exercise three or more times per week for 
at least 30 min/day; are participating in an exercise 
programme aiming to prevent recurrence of LBP; are 
achieving more than 150 min of moderate or vigorous- 
intensity physical activity weekly (across a minimum of 3 
days/week); spinal surgery in the preceding 6 months; 
are pregnant; or have inadequate English to complete 
outcome measures (ie, questionnaires). In addition to 
these criteria, participants will be informed of the loca-
tions of the clinics for the three face- to- face sessions for 
the intervention group and will only be enrolled if they 
are willing to travel to one of these clinics for all three 
sessions.
Clinician recruitment
Approximately 20–30 registered and experienced phys-
iotherapists will deliver the walking and education 
intervention at private physiotherapy clinics across 
Australia. Clinicians will be invited to participate via a 
purposeful sampling technique, based on location of 
their workplace and clinical experience.
Clinician training
Each physiotherapist will undertake 3 hours of online 
training on behaviour change and coaching, through 
modules developed by Wellness Coaching Australia ( www. 
well ness coac hing aust ralia. com. au).21 These short- course 
modules were modified in collaboration with Wellness 
Coaching Australia to cover the principles relevant to 
the trial: skills and principles of coaching, applications 
of motivational interviewing, building self- efficacy, goal 
setting and implementing action. This training aimed to 
optimise patient compliance with the intervention.
All physiotherapists will then be trained by a researcher 
in the study intervention procedures in a single 
Figure 1 Flow chart of WalkBack Trial. LBP, low back pain; PA, physical activity.
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face- to- face session lasting 90 minutes. Clinicians will 
receive bimonthly email updates/reminders on trial 
procedures and tips for optimal delivery of the interven-
tion. In addition, there will be optional online meetings 
three times per year for the treating clinicians to discuss 
any challenges in delivering the intervention.
Participant recruitment
Participants will be recruited either via community adver-
tising (eg, via social media, company newsletters, flyer 
distribution) or through clinician referrals (eg, general 
practitioners (GPs), physiotherapists, chiropractors, 
surgeons). Community advertising will direct enquiries to 
the trial website ( www. walkbacktrial. com), where poten-
tial participants can find out more about the trial and 
express an interest in participation.
For referral through clinicians, patients being 
discharged from primary care clinics following recovery 
from an episode of non- specific LBP will have the trial 
explained to them by the clinician. For those interested 
and potentially eligible, the clinician will provide a flyer 
that includes contact details of the research team and a 
link to the project’s website. Potential participants can 
contact the research team (either via phone, email or the 
website) or alternatively opt to have the research team 
contact them directly by consenting to allow the clinician 
to forward contact details. Referring clinicians will be 
reimbursed for enrolled participants for the time taken 
to explain the trial and preliminary screening of potential 
participants. All potential participants will be screened 
for eligibility over the phone by a member of the research 
team prior to inclusion, will have the details of the trial 
explained to them and will have the opportunity to have 
all queries answered prior to enrolment.
Consent
All interested individuals who are eligible and agree to 
participate will be sent a link to an electronic baseline 
questionnaire. The first page of the questionnaire will 
include the Participant Information and Consent Form 
and will require informed consent (tick- box response) 
prior to commencement of the questionnaire and enrol-
ment into the trial (online supplemental appendix 1).
Baseline assessment
Following informed consent, participants will complete 
the baseline assessment. This assessment will involve 
collection of personal information regarding age, 
gender, work and educational status, and relevant history 
of back pain (eg, number of previous episodes, dura-
tion of most recent episode and perceived triggers). 
Emotional status will be collected as a baseline measure 
using the Depression, Anxiety and Stress Scale-21 Items.22 
Further outcomes detailed in the ‘secondary outcomes’ 
section will be collected as well. These questionnaires 
will be collected via an online, study- specific survey using 
Research Electronic Data Capture (REDCap) systems, 
adhering to accurate and confidential data collection and 
storage.
Randomisation
Immediately after completing the baseline assessment, 
participants will be randomly allocated to either the 
walking and education programme (intervention) or no 
treatment (control) group. Randomisation using a 1:1 
allocation ratio will be conducted using a schedule that 
has been pregenerated by an online programme, by an 
investigator not involved in participant recruitment or 
assessment. Randomisation will use randomly permuted 
blocks of 4, 6 and 8 and be stratified by history of >2 
previous lifetime episodes of LBP (known to be a prog-
nostic factor for recurrence),4 and recruitment from 
the community or clinician referral. Once allocated, an 
unblinded member of the research team will notify the 
participant of the allocation. Study participants will only 
be considered enrolled in the trial once randomisation is 
complete. For those allocated to the walking and educa-
tion group, the research assistant will make an appoint-
ment for them with a study clinician at an accessible 
location of their choice.
Study treatment
Control group: no treatment
This group will not be provided with any treatment as 
part of involvement in the trial. Instead, they will be free 
to engage in strategies to prevent or treat LBP as they 
choose with no restrictions due to participation in the 
study. This approach was selected as there was strong 
agreement among the research team and consumer 
representatives that this represented the most important 
and real- world comparison to the intervention. The 
services and treatments used by participants throughout 
the trial will be recorded, reported in future publications 
and used to inform an appropriate and comprehensive 
cost- effectiveness analysis.
Intervention group: walking and education
The intervention is summarised in table 1 and comprised 
two core elements:
Individualised and progressive walking programme
Participants allocated to the walking and education group 
will attend a total of three face- to- face sessions with a phys-
iotherapist (baseline, 1 month and 3 months) to prescribe 
a progressive and individualised walking programme and 
to receive education. Participants will also receive three 
over the phone sessions at 2 and 6 weeks and a reinforce-
ment session at 6 months, delivered by the same clinician 
who conducts the face- to- face consultations. The broad 
aim of the programme is to design a progressive and 
individually tailored walking programme collaboratively 
with each participant, reaching a minimum dosage of 
five times per week, for at least 30 min by the end of the 
programme.
During the first face- to- face session, the physiotherapist 
will discuss relevant history of LBP with the participant 
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and carry out an appropriate history and physical exam-
ination, which aids in individualisation of the walking and 
education components of the intervention. A prescription 
tool (online supplemental appendix 2) has been devel-
oped to guide the therapists in the initial prescription of 
the walking programme. This prescription is based on a 
participant’s current level of walking for the purpose of 
exercise (as opposed to travel or incidental activity), age 
and body mass index.
Though the prescription tool will inform the initial 
walking programme, the therapist in consultation with the 
participant can modify the walking programme based on 
any relevant factors including time restraints, functional 
limitations, comorbidities, lack of confidence to achieve 
set goals, environmental barriers (ie, safety, lighting, 
surfaces), and so on. The delivery of the intervention is 
framed around the principles of health coaching, with 
the intention of supporting behaviour change and opti-
mising compliance. Health coaching will involve partici-
pant- led and clinician- assisted goal setting, promotion of 
self- efficacy, identification of barriers and facilitators to 
engagement in the walking programme and appropriate 
troubleshooting to resolve these.
Initial emphasis will be placed on the progression of 
dosage of intentional walking, starting at a minimum 
frequency of three times per week, and working towards 
walking five times or more per week. Once achieved, 
participants will be encouraged to increase the intensity 
Table 1 Intervention description using the Template for Intervention Description and Replication (TIDieR) checklist
1.Brief name The WalkBack Trial
2. Why Low back pain (LBP) is recognised globally as a prevalent, costly and disabling condition. 
Recurrences are common and contribute to much of the burden of LBP. Current evidence 
favours exercise and education for prevention of LBP, but an optimal intervention has not yet 
been established. Walking is a simple, widely accessible, low- cost intervention that has yet to be 
evaluated.
3. What materials Participants allocated to the walking/education intervention will receive:
 ► Sessions with a physiotherapist with the primary aim to design a progressive and individually 
tailored walking programme.
 ► Education which will focus on a modern understanding of LBP that reduces the threat and fear 
associated with pain and advice on strategies to reduce the risk of a recurrence of LBP.
 ► A wearable physical activity tracker to measure daily steps.
 ► A walking diary to act as a motivator in completing the programme and provide a degree of 
accountability.
4. What procedures  ► The initial of three face- to- face contacts with the clinician will be used to collaboratively design 
a walking programme and provide education and advice related to LBP and the rationale for 
undertaking the programme.
 ► The telephone and face- to- face sessions will use health coaching principles to identify barriers 
and facilitators to engagement in the walking programme, and to provide support to assist 
participants achieve the walking goals or modify the programme as required.
 ► The follow- up face- to- face contacts with the clinician will focus on progression of the walking 
programme by a combination of increasing frequency, duration and intensity throughout the 
programme.
5. Who provided Clinicians with a tertiary qualification in physiotherapy who have received training through 
Wellness Coaching Australia on the topic of behaviour change and coaching will deliver the 
intervention.
6. How  ► The initial assessment and tailored walking programme will be reassessed and progressed 
during the three face- to- face consults with the clinician.
 ► Coaching throughout the programme will be delivered both over the phone and in the face- to- 
face sessions.
7. Where The intervention will be delivered at approximately 25 private physiotherapy clinics in Australia.
8. When and how much  ► Following randomisation, those in the walking/education intervention will receive six sessions 
with a physiotherapist.
 ► Participants will be booked in for an initial consult (week 0) with a physiotherapist lasting 
approximately 45 min.
 ► The telephone- based coaching will occur at three time points (weeks 2, 8 and 26), taking 
approximately 15 min based on each participant’s requirement.
 ► Two face- to- face follow- up sessions will take place in weeks 4 and 12 and will last 
approximately 30 min.
9. Tailoring  ► The walking programme will be tailored to participant goals, current walking capacity and 
participant preferences.  on A
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of their programme. This can be done in various ways 
(faster walking, incorporating hills/stairs, or progressing 
to jogging as guided by the clinician) based on individual 
preference. This flexibility in progression aims to main-
tain motivation to continue the programme.
Participants will be progressed through the programme 
individually, based on their response during the 
programme. In some instances, it may be inappropriate 
for participants with multiple comorbidities or those 
deconditioned at commencement of the programme to 
reach standard targets, hence the intervention will be 
individualised, and an appropriate target will be negoti-
ated. At each face- to- face session a progression goal will be 
set for the following face- to- face visit. During telephone- 
delivered sessions, between face- to- face visits, the thera-
pist will reassess the goal with the participant and modify 
as required.
Another method to facilitate compliance is the provi-
sion of a pedometer and walking diary to act as motivators 
in completing the programme and provide a degree of 
accountability. Pedometers and diaries have been iden-
tified as effective tools for promoting motivation and 
participation in physical activity.23 24 The results recorded 
in the diary will be used by the physiotherapist at face- to- 
face visits and over the phone sessions, to progress each 
individual’s walking programme, discuss barriers to prog-
ress and motivate compliance.
Education component
This component will be delivered alongside the walking 
programme. Education will focus on a modern under-
standing of LBP that reduces the threat and fear asso-
ciated with pain, which has been shown in previous 
research to reduce the likelihood of care seeking.25 Addi-
tional education will focus on simple daily strategies to 
reduce the risk of a recurrence of LBP. The strategies will 
be individualised and based on the lifestyle of the indi-
vidual and the factors triggering previous LBP episodes. 
Based on current evidence of risk factors the education 
will typically involve advice and strategies for avoiding 
sustained sitting, awkward postures and education in safe 
manual- handling techniques.4
COVID-19 addendum
Due to the COVID-19 pandemic, the decision was made 
to offer the intervention arm of the trial via telehealth 
starting on 1 April 2020. Instead of participants allo-
cated to the intervention group meeting a physiother-
apist face to face for three of the six sessions, these 
sessions are now available via telehealth (ie, videocon-
ferencing) to ensure the safety of both participants and 
the clinicians.
The intervention is primarily based around educa-
tion, health coaching and prescription of a walking 
programme, all of which can be delivered effectively in 
either a telehealth or in- person format. These changes 
have been approved by the Macquarie University Ethics 
Committee and an update has been made to the ANZCTR.
Data collection and outcome measures
The outcomes collected in the trial and the time points at 
which they are collected are summarised in table 2.
Primary outcome
The primary outcome will be the number of days from 
randomisation to first self- reported recurrence of an 
episode of LBP causing activity limitation. This is defined 
as a return of LBP lasting at least 24 hours with a pain 
intensity >2 (0–10 Numeric Pain Rating Scale) with 
‘activity limitation’ confirmed by a response of ‘some-
what’ or greater on an adapted version of item PI9 of the 
PROMIS item bank (‘How much did low back pain inter-
fere with your day to day activities?’ Not at all; A little bit; 
Somewhat; Quite a bit; Very much).26
To ensure precise estimates of days until recurrence 
of LBP, participants will be contacted each month by 
email and will be sent a questionnaire asking if they have 
had a recurrence of LBP. Participants not responding to 
monthly email within 48 hours will be sent a reminder 
email, and then contacted by phone 48 hours later if no 
response to the questionnaire has been obtained. Partici-
pants will be followed up for this outcome for a minimum 
of 12 months, and up to a maximum of 36 months (ie, 
conclusion of the trial), dependent on when they are 
randomised.
Secondary outcomes
Secondary outcomes, collected at baseline and months 3, 
6, 9 and 12 (unless otherwise stated), will include:
 ► Number of days from randomisation to first self- 
reported recurrence of an episode of LBP. This will 
be reported each month.
 ► Number of days from randomisation to first self- 
reported recurrence of an episode of LBP leading to 
care seeking with a healthcare provider (eg, GP, phys-
iotherapist, chiropractor, massage therapist, acupunc-
turist, and so on). This will be reported each month.
 ► Health- related quality of life and a related economic 
evaluation measured by the EuroQol 5- Dimension 
5- Level (EQ- 5D- 5L).27
 ► Condition- specific functioning (related to LBP) will 
be measured by the Roland- Morris Disability Ques-
tionnaire (RMDQ).28
 ► Physical activity will be collected using a modi-
fied version of the International Physical Activity 
Questionnaire- Short Form29 at baseline, months 3 
and 12.
 ► Objective measure of physical activity using ActiGraph 
data from 7 days wear time at 3 months.
 ► Self- reported cointerventions received for treatment 
or prevention of LBP (external to that received in the 
intervention).
Compliance measures for those in the intervention will 
include:
 ► A record of attendance (yes/no) as documented by 
the clinician providing the six coaching sessions.
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 ► Modified version of the Brief Adherence Rating 
Scale30 ranging from 0 (not compliant at all) to 10 
(very compliant) reported by participant at months 
3, 6, 9 and 12.
 ► Walking duration and pedometer- based step count 
recorded in the walking diary for initial 3 months of 
the programme (converted to a percentage of the 
weekly individual goal).
For quality control of the programme delivery, a 
member of the research team will meet with each clini-
cian following their 5th and 10th participants. The 
programme delivered to that participant will be discussed 
to ensure the intervention continues to be delivered to a 
satisfactory standard.
Adverse events (AEs) will be monitored and defined 
as any new medical condition or exacerbation of an 
existing condition as reported by the participants during 
the study. Questioning of AEs will occur at months 3, 
6, 9 and 12. Serious AEs will also be monitored and are 
defined as any untoward medical occurrence that results 
in death, is life threatening, requires hospitalisation 
or results in significant disability. We will comply with 
Table 2 Overview of outcomes, outcome measures, instruments and assessment time points
Outcomes Outcome measures Instrument
Assessment time 
point*
Primary Outcome  
  Activity- limiting LBP 
episode
Number of days from randomisation until 
recurrence of an episode of LBP causing 
activity limitation.
Self- report
Adapted version of item PI9 
of the PROMIS item bank
Monthly
Secondary Outcomes
  LBP episode Number of days from randomisation until 
recurrence of an episode of LBP >2/10.
Self- report Monthly
  Care- seeking LBP episode Number of days from randomisation until 
recurrence of an episode of LBP resulting 
in care seeking.
Self- report Monthly
  Health- related quality of life EQ- 5D- 5L T0, T1, T2, T3, T4
  Disability RMDQ T1, T2, T3, T4
  Emotional status Depression, anxiety and stress DASS-21 T0
Health economics- related outcomes
  Healthcare services used Hospitalisation, healthcare, medication use Self- report T0, T1, T2, T3, T4
  Work absenteeism Hours of missed work attributable to LBP Self- report T0, T1, T2, T3, T4
  Other services used Meals service, community care, cleaning 
services, and so on
Self- report T0, T1, T2, T3, T4
  Cointerventions received   Self- report T1, T2, T3, T4
Physical activity Outcomes
Time in sitting, walking, moderate and 
vigorous physical activities
IPAQ- SF T0, T1, T4
Physical activity counts (7 days) ActiGraph T2
Walking speed† 10MWT T0, T1
Compliance Measure
  Attendance record†   Clinician reported T1, T2
  Adherence rating†   BARS (self- report) T1, T2, T3, T4
  Daily step count† Step count using pedometer Walking diary 0–3 months
  Intentional walking† Minutes reported for intentional walking for 
exercise
Walking diary 0–3 months
Adverse Events
Self- report T1, T2, T3, T4
*Assessment time points: T0=baseline pre- intervention, T1=month 3 post- intervention, T2=month 6 post- intervention, T3=month 9 post- 
intervention, T4=month 12 post- intervention.
†Completed by intervention group only.
BARS, Brief Adherence Rating Scale; DASS-21, Depression, Anxiety and Stress Scale-21 Items; EQ- 5D- 5L, EuroQol 5- Dimension 5- Level; 
IPAQ- SF, International Physical Activity Questionnaire- Short Form; LBP, low back pain; 10MWT, 10m walk test; PROMIS, Patient- Reported 
Outcomes Measurement Information System; RMDQ, Roland- Morris Disability Questionnaire.
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relevant Australian guidelines and requirements for 
reporting AEs.31
Sample size
Sample size was calculated for the primary outcome 
using PASS software based on the method of Lakatos.32 
Specifications include a two- sided log- rank test, type I 
error=0.05, power=80%, 24- month accrual period and 
12- month follow- up period. We used a conservative esti-
mate of 30% recurrence rate at 12 months in the control 
group, a rate observed in previous work by Stanton et 
al.33 To detect a 25% relative reduction in recurrence 
rate (from 30% to 22.5%), 349 participants per group 
are required. A 25% relative reduction is large enough 
to have important public health implications. Sample size 
calculations allowed for 1% loss to follow- up per month. 
Higher recurrence rates such as those from our recent 
cohort study (69%)4 would provide substantially more 
power (>99%).
For the secondary survival analyses, using an episode 
of LBP resulting in care seeking as the recurrence defini-
tion, we have 80% power to detect a 28% relative reduc-
tion assuming the recurrence rate is 25% in the control 
group (from 25% to 18%) or 23% relative reduction if 
the control group recurrence rate is 35% (from 35% to 
27%). There are limited data available on rates of recur-
rences resulting in care seeking, but our recent cohort 
study found 1- year rates of recurrences resulting in care 
seeking to be approximately 40% which would enable 
us to identify even smaller effects (risk reduction=21% 
(from 40% to 32%)).4
For the secondary continuous outcomes, we have 91% 
power to detect a 0.25 SD difference between the means of 
two groups. For example, for the key secondary outcome 
of RMDQ we would be interested in a 2- point difference 
and assuming a common SD of 6 points.
Blinding
Due to the nature of the intervention, complete blinding 
will not be possible. The participants will not be blinded 
to group allocation. Members of the research team 
responsible for data collection and statistical analysis will 
be blinded to group allocation. Blinded interpretation of 




The primary intention- to- treat analysis will assess differ-
ence in survival curves (days to recurrence) using the 
log- rank statistic. Cox regression will be used to assess 
the effect of treatment group on HRs and to adjust for 
prognostic factors for recurrence of LBP,34 if these are 
unbalanced between groups despite randomisation. The 
proportional hazards assumption will be tested using the 
time- dependent covariate method. For the secondary 
outcome of time to recurrence an analogous survival 
analysis will be conducted. The effect of including the 
variables that were used for the stratified randomisation 
as strata in these analyses will also be assessed. The psycho-
logical, quality of life and disability scales will be treated 
as continuous outcomes. Multiple linear regression will 
be used to test for differences in means between groups, 
adjusted for potential confounders. Transformations will 
be applied if needed to meet model assumptions. Linear 
mixed modelling will be used to take account of correla-
tion between measurements within an individual for 
repeated measurements over time.
Economic evaluation
The economic evaluation will be conducted from the 
societal perspective and according to the intention- to- 
treat principle. Costs incurred from a societal perspective 
will be self- reported using a purpose- built questionnaire. 
Cost data will include healthcare utilisation (eg, visits to 
healthcare providers, medication and hospitalisation) 
and productivity loss (work absenteeism) due to LBP.
Costs of the walking and education programme will be 
estimated using a bottom- up approach. We will register 
the number of sessions, personnel involved, and their time 
spent, and materials and practice space used. Costs of the 
time spent by participants on the intervention will also be 
measured. Costs to the healthcare system will be valued 
at standard rates published by the Australian government 
(eg, Medical Benefits Scheme), or as reported by partic-
ipants (eg, private physiotherapy). Community services 
(eg, gym attendance) and other out- of- pocket costs will 
be as reported by participants. The costs of work absen-
teeism will be estimated by the number of days absent 
from work multiplied by the average wage rate.
The cost- effectiveness analysis will compare the walking 
and education programme to the control group using 
the primary outcome as the measure of effectiveness. 
A model proposed by Latimer35 for survival analysis for 
economic evaluations alongside RCTs will be used. A 
cost- utility analysis will also be performed with quality- 
adjusted life years (QALYs) as outcome. QALYs will be 
based on the EQ- 5D- 5L. Incremental cost- effectiveness 
ratios will be calculated by dividing the between- group 
difference in costs by the between- group difference in 
effects (ie, costs per recurrence- free month gained). Cost- 
effectiveness ratios will be estimated using bootstrapping 
techniques (5000 replications) and graphically presented 
on cost- effectiveness planes. Acceptability curves and net 
monetary benefit will also be estimated.
Monitoring
Due to the expected low risk of harm, we have not 
planned a data safety monitoring committee. There is 
also no planned interim analysis or stopping guidelines.
ETHICS AND DISSEMINATION
Approved by Macquarie University Human Research 
Ethics Committee (reference: 5201949218164, 3 May 
2019). Study findings will be disseminated through 
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publication in peer- reviewed journals and conference 
presentations. Any protocol amendments will be detailed 
in the trial registration following ethics approval. The 
trial has been endorsed by the ANZMUSC Clinical 
Trials Network indicating its high clinical priority and 
quality, importance to consumers, patients, clinicians 
and policymakers and its potential to improve patient 
outcomes.
Deidentified data and statistical code will be made 
available on request soon after each report of the data 
has been published. Different aspects of the data will be 
published separately, which will determine when those 
data are publicly available. A data- sharing agreement 
will require a commitment to using the data only for 
specified research purposes, to securing the data appro-
priately and to destroying the data after a nominated 
period.
Trial status
Recruitment commenced in September 2019. As of 
September 2020, the trial has recruited 230 participants. 
The trial is anticipated to conclude data collection on 31 
December 2022.
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